Search

everythinglearnresearchcommunity

for

Search:↓

Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.

Tirzepatide may improve hair loss by reducing insulin resistance.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Baricitinib effectively treats severe alopecia for up to 104 weeks.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Tranilast successfully treated a man's skin sarcoidosis when other treatments failed.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Tedisamil and glibenclamide affect cromakalim and minoxidil sulphate differently in rat aorta.

Saw palmetto extract is effective and safe for treating lower urinary tract symptoms, working as well as certain medications, and works even better in severe cases.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

The patch effectively promotes hair growth for alopecia areata without pain.

Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.

Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.